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1. Introduction 
Brain peptides eem to be synthetized in neuronal 
systems as larger Mr precursors. A 15 000 Mr form of 
the tetradecapeptide somatostatin was characterized 
in hypothalamic extracts [1,2] and its digestion by 
copurified enzymes led to lower M, somatostatin-like 
species [11. Pre-prosomatostatins with comparable 
size were identified by cell-free translation of mRNA 
extracted from the Brockmann organ of the Anglerfish 
[3,4]. The cloning of cDNA coding for somatostatin 
precursors from the pancreas was accomplished by 
2 groups and indicated some divergence inthe sequence 
of the predicted pre-prohormone [5,6]. These obser- 
vations were interpreted [ 51 as suggesting the existence 
of several (at least 2) genes coding for 2 distinct 
somatostatin sequences: the normal tetradecapeptide 
(somatostatin I) and its derivative (Tyr’-Gly”; 
somatostatin II). In spite of obvious analogies of 
molecular size with the pancreatic precursor, little is 
known about the structure and the function(s) of the 
somatostatin precursor produced in the central ner- 
vous system; in particular, the peptide sequences 
recognized by the putative converting enzyme(s). 
Here we demonstrate hat hypothalamic extracts con- 
tain protease capable of converting selectively the 
Mr 15 000 precursor into somatostatin I as evidenced 
by radioimmunological and high-pressure liquid 
chromatography (HPLC) criteria. 
2. Experimental 
Phenyhnethylsulfonylfluoride (PMSF), trasylol 
and pepstatin were purchased from Sigrria (St Louis 
MO). Acetronile HPLC grade, was obtained from 
Prolabo. The synthetic somatostatin was furnished by 
Clin-Midy (Montpellier) [7], and its purity was 
checked both by HPLC and mass pectrometry thanks 
to the Service central d’analyse, CNRS (Vernaison). 
The antiserum was provided by URIA (Dr Dray) 
Institut Pasteur (Paris). The analogs (Tyr’r) and (Tyr’)- 
somatostatin were from Bachem (California). 
Ail experiments were run at 4°C. Mice hypothalami 
(25 fragments) were removed under a binocular micro- 
scope (Nikon type 102) immediately after sacrifice 
and homogenized in a Potter-Elvejhem (clearance 
0.25 m) in 3 ml 0.1 N HCl, 8 M urea containing 
250 kallikrein inhibitor units/ml. Centrifugation was 
performed for 1 h at 100 000 X g in a SW 50 rotor on 
a Beckman L565 centrifuge. The supematant solu- 
tion was submitted to molecular sieve filtration on a 
Sephadex G-50 column equilibrated and eluted with 
0.1 N HCOOH containing 0.5 mM PMSF and 1 mg 
pepstatin/l. Each fraction was tested by a radioim- 
munoassay procedure (RIA) using anti-somatostatin 
3638 antiserum. The free iodinated tracer was sepa- 
rated from the antibody bound by propanol precipi- 
tation after addition of non-immune serum in each 
fraction. Controls were routinely performed as in [l] 
to exclude RIA artefacts possibly arising from degra- 
dation of the tracer or its sticking to protein compo- 
nents of the samples. Separation and identification 
of the tetradecapeptide somatostatin were carried 
out by HPLC on a SP 8000 (Spectra Physics) apparatus 
using a reverse phase column tichrosorb 10 RP 18 
(250 X 4.6 mm) from Merck. The column was eluted 
isocratically with a mixture containing 34% (v/v) 
acetonitrile and 66% (v/v) ammonium acetate 0.05 M, 
adjusted to pH 4. At the end of the run, a linear 
gradient of acetonitrile was generated in order to 
release ail fragments possibly with a higher etention 
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time. Before each run all the collection tubes were 
coated with bovine serum albumin. After lyophilisa- 
tion each eluted fraction was tested by RIA. 
3. Results and discussion 
Chromatography of mice hypothalami extracts on 
a Sephadex G-SO column separated 3 major immuno- 
reactive peptides with apparent Mr : 15 000,600O and 
1600. The smaller immunoreactive components coelute 
with iodinated somatostatin added as internal marker 
(fig.1). One aliquot of this species was injected directly 
on the HPLC system and tested by RIA. The immuno- 
reactive material was eluted as a single peak with the 
same retention time as the tetradecapeptide somato- 
statin (not shown). The 15 000 Mr material recovered 
after Sephadex G-50 fractionation of acid/urea 
extracts of hypothalamus, was pooled and the pH was 
adjusted to 6.0 in the presence of proteases inhibitors. 
If this material was immediately re-submitted to 
Sephadex G-SO fractionation the apparent Mr of the 
15 000 Mr somatostatin-like species was found 
unaffected (fig.2, top). In contrast when incubated 
under the same conditions, for 8 h at 37”C, the 
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Fig.1. Fractionation of somatostatin-like forms extracted 
from mouse hypothalamus. The acid-urea extract was 
fractionated on a Sephadex G-SO column (95 X 1.2 cm) 
eluted with 0.1 N HCOOH containing 0.5 mM PMSF and 
1 mg pepstatin/l. [1Z51]Somatostatin was added as internal 
marker, its elution position is shown by the arrow. A,, nm 
(o---o) and somatostatin immunoreactivity (e-o) were 
measured in each fraction (1 ml). B,/B, X 100 represent he 
percentage of antibody-bound [‘251]somatostatin tracer. 
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Fig.2. Processing of the 15 000 Mr prosomatostatin. The 
Mr 15 000 form recovered from tig.1 fractionation was resub- 
mitted to the same chromatography as in fgl but on a dif- 
ferent size column (45 X 1.2 cm) (top), and after incubation 
at pH 6 for 8 h at 37’C (bottom). Each fraction (1 ml) was 
analyzed by RIA with antiserum 3638. The arrow indicated 
the elution peak of [ 12sI]somatostatin used as internal marker. 
pattern of somatostatin-like material recovered after 
gel filtration indicated that 3 species of somatostatin 
withMr 15 000,600O and 1600 were generated (fig.2, 
bottom). The proteolytic activities co-eluting with 
the 15 000 Mr prosomatostatin apparently generated 
the same species as found in the crude extract. If 
the 15 000 Mr prosomatostatin was first purified by 
affinity chromatography, this species appeared stable 
under the conditions of the maturation experiment 
(not shown). 
To demonstrate that at least one of the proteolytic 
activities coeluting with the 15 000 MI precursors 
species is specific, the smaller somatostatin-like 
product (fig.2, bottom) was analyzed by HPLC. The 
material of lowest apparent Mr on Sephadex G-50 
was pooled, lyophylized and redissolved in 1 M acetic 
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Fig.3. High-pressure liquid chromatography identification of 
the species generated by processing of the 15 OOOMr precursor. 
The fractions of somatostatin-like immunoreactivity generated 
in fig.2 (bottom) experiment and eluted as ]r2sI]somatostatm 
were pooled and analyzed by HPLC on a 10 RP 18 column 
(Merck) (250 X 4.6 mm) with 35% acetronlle in the 50 mM 
acetate ammonium (pH 4) at a flow rate of 1 ml/mm Each 
fraction was assayed by the antisomatostatin antibodies 
(histogram). The arrows indicate the elution peaks of A, 
Tyr” somatostatin B; somatostatinr4 and C; Typ somato- 
statin, respectively. Immunoreactive somatostatin was 
expressed in pg/fraction. 
acid and injected directly on the HPLC system. The 
immunoreactive species were eluted as a single peak 
(fIg.3) with a retention time indistinguishable from 
the one of the tetradecapeptide somatostatin I. No 
other material was detectable by RIA (fig.3). The 
presence of large quantities of trypsin inhibitors was 
found to be necessary to prevent he generated soma- 
tostatin from its subsequent degradation by trypsin- 
like enzymes (not shown). 
The predicted sequences for the prosomatostatins 
coded by mRNA from Angler&h pancreas indicate 
the presence of several Lys or Arg residues located 
either inside or outside the tetradecapeptide sequence; 
only a single dibasic stretch located at position - 1, 
-2 (Lys -1, Arg -2), can be predicted [5,6]. There- 
fore, the converting enzymes must exhibit a high 
specificity for such a signal to release selectively the 
l-14 somatostatin. If this signal appears to be the 
same for the prosomatostatin from mouse hypo- 
thalamus, then the above data would suggest that such 
a selective dibasic esteropeptidase i  present in hypo- 
thalamic extracts. This enzyme would be responsible 
for the observed selective conversion of the 15 000 M, 
prosomatostatin i to the l-14 tetradecapeptide. 
These data do not suggest that a second prosomato- 
statin is present in noticeable amounts in the hypo- 
thalamic extracts as judged by the fact that only a 
single 1-14 peptide could be detected after the pro- 
cessing of the 15 000 form. An observation consistent 
with those made in [8] in the pancreas. They open 
the way to a further identification of this processing 
enzyme of brain peptides precursors. 
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